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In Traditional Chinese Medicine (TCM), treatment based on ZHENG (also called TCM syndrome and pattern) diﬀerentiation has
been applied for about 3 thousand years, while there are some diﬃculties to communicate with western medicine. In the present
work, metabonomic methods were utilized to diﬀerentiate ZHENG types and evaluate the therapeutic eﬃciency of Fuzhenghuayu
(FZHY) tablet in hepatitis-B-caused cirrhosis (HBC). Urine samples of 12 healthy volunteers (control group, CG) and 31 HBC
patients (HBCG) were analyzed by gas chromatography mass spectrometry (GC/MS) and multivariate statistical analysis. The
signiﬁcantly changed metabolites between CG and HBCG were selected by PLS-DA loading plot analysis. Moreover, 4 ZHENGs
were diﬀerentiated mutually, suggesting that there was urine metabolic material basis in ZHENG diﬀerentiation. The eﬃciency of
FZHY tablet on subjects with spleen deﬁciency with dampness encumbrance syndrome (SDDES) and liver-kidney yin deﬁciency
syndrome (LKYDS) was better than that of other syndromes. The eﬃciency of FZHY treatment based on ZHENG diﬀerentiation
indicated that accurately ZHENG diﬀerentiating could guide the appropriate TCM treatment in HBC.
1.Introduction
Cirrhosis and its complications are one of the main causes
of mortality [1] especially for individuals aged 45 to 54
years [2]. Hepatitis B virus (HBV) infection is one of the
most common viral infections in humans. Approximately
350 million people have been chronically infected by HBV
[3], and around 20% to 30% of them will result in cirrhosis
[4]. To date, the deﬁnite and indeﬁnite duration treatments
with interferon and nucleotide analogue, respectively, are
two ﬁrst line strategies in western medicine [4]. Facing
the sustained high morbidity and mortality, new eﬀective
therapeutic protocols of HBC are imperative. As a holistic
and multitarget approach, TCM has shown some advantages
on the treatment of those complicated chronic diseases [5–
7].
WithincreasingattentionspaidtoTCM,manyresearches
[5–7] about the curative eﬀect of Chinese medicinal and
formulas were conducted but lack direction of TCM the-
ory. TCM is a large and complex system, and ZHENG
diﬀerentiation and treatment (Bian Zheng Lun Zhi) is one
of its essences. To further explaination, the diagnosis that
guides treatment of TCM is called ZHENG (TCM syndrome
or pattern), a temporary state at one time and which is
deﬁned by symptoms and signs. It could be assessed by four
diagnostic methods (looking, listening and smelling, asking,
andtouching)[8].Andthesamediseasecanusuallymanifest
in diﬀerent syndromes, so patients with diﬀerent ZHENG2 Evidence-Based Complementary and Alternative Medicine
types may be treated by diﬀerent rules and therapeutic
regimen. Based on the holistic and systemic characteristics
of ZHENG, metabonomics [9], genomics [10], proteomics
[11], and the integration of them [12] were introduced to
the research of ZHENG diﬀerentiation.
The marketed Fuzhenghuayu tablet is a TCM prescrip-
tion including Radix Salvia miltiorrhizae, Cordyceps mycelia
extract, Semen Persicae, Gynostemma pentaphyllum Mak,
Pollen Pini and Fructus schisandrae chinensis.T h er e c i p e
composition was directed by the therapeutic method of
invigorating blood transforming stasis and boosting essence
supplementing deﬁciency [13]. In the present study, urine
Metabonomics [14] based on gas chromatography mass
spectrometry (GC/MS) and multivariate statistical tech-
niques was utilized to diﬀerentiate four ZHENG types of
HBC in the molecular level and evaluate the therapeutic
eﬀects of FZHY tablet for diﬀerent ZHENG types. To
our knowledge, this study is the ﬁrst report of urinary
Metabonomics method used to investigate the therapeutic
eﬀects of FZHY tablet for diﬀerent ZHENGs.
2.MaterialsandMethods
2.1. Subjects and Experiment Design. Twelve healthy volun-
teers and 31 patients from Shanghai Shuguang Hospital
(Shanghai, China) were enrolled in the study. The healthy
volunteers without any treatment were considered as CG.
Allofpatientswereaﬀectedwithhepatitis-B-causedcirrhosis
(HBC) and regarded as disease group (HBCG). The patients
were classiﬁed into 4 ZHENG types, including spleen
deﬁciency with dampness encumbrance syndrome (SDDES,
n = 7), liver-gallbladder dampness-heat syndrome (LGDHS,
n = 7), liver-kidney yin deﬁciency syndrome (LKYDS, n =
10), and blood stasis syndrome (BSS, n = 7). All of them
were treated with the same formula by oral administration.
Then metabonomic detection and analysis was performed
to evaluate the therapeutic eﬀect on HBC patients with
diﬀerent ZHENG types. The clinical study was approved by
the local ethics committee and all of the recruited persons
weregiveninformedconsent.Diagnosisstandardofcirrhosis
is referred to “Chronic hepatitis B prevention and treatment
guidelines.” [15]. And all cases of HBC caused by other
factors such as hepatitis C infection, alcohol consumption,
and usage of drugs with hepatotoxicity were ruled out before
all the subjects entered the study. The TCM ZHENG types
wereidentiﬁedbythreechiefordeputyphysicians,according
to “evaluation criteria of the clinical diagnosis, drug eﬃcacy,
and ZHENG diﬀerentiation for cirrhosis (pilot program)”
[16]. The study was performed in accordance with the
principles contained in the Declaration of Helsinki.
2.2. Chemicals and Drugs. Ethyl chloroformate (ECF), pyri-
dine, anhydrous ethanol, sodium hydroxide, chloroform,
and anhydrous sodium sulfate were analytical grade from
China National Pharmaceutical Group Corporation (Shang-
hai, China). L-2-chlorophenylalanine (Shanghai Intechem
Tech. Co. Ltd., China) was used as an internal quality
standard which was prepared in the ultrapure water from
a Milli-Q system (Millipore, USA). FZHY tablets were
provided by Shanghai Huanghai Pharmaceutical Co., Ltd.
2.3. Sample Collection and Preparation. Urina sanguinis was
collectedfrom12healthysubjectsand31HBCpatientswhen
they were enrolled in the study. And after 12 and 24 weeks of
treatment the patients were asked for urina sanguinis again.
Urine samples were stored at −80◦C until GC-MS assay.
All these samples were thawed in ice water bath and
vortex-mixed before analysis. Each 600µLa l i q u o to f
standard mixture or urine sample was added to a screw
tube. After adding 100µL of l-2-chlorophenylalanine
(0.1mgmL−1), 400µL of anhydrous ethanol, and 100µLo f
pyridine to the urine sample, 50µL of ECF was added for
ﬁrst derivatization at 20.0±0.1◦C. The pooled mixtures were
sonicated at 40kHz for 60s. Subsequently, extraction was
performed using 300µL of chloroform, with the aqueous
layer pH carefully adjusted to 9-10 using 100µL of NaOH
(7molL−1). The derivatization procedure was repeated
with the addition of 50µL ECF into the aforementioned
products. After the two successive derivatization steps, the
o v e r a l lm i x t u r e sw e r ev o r t e x e df o r3 0sa n dc e n t r i f u g e df o r
3min at 3000rpm. The aqueous layer was aspirated oﬀ,
while the remaining chloroform layer containing derivatives
was isolated and dried with anhydrous sodium sulfate
and subsequently subjected to GC-MS. The derivatization
method referred to [17].
2.4. Data Acquisition. All GC-MS analyses were performed
by a mass spectrometer 5975B (Agilent technologies, USA)
coupled to an Agilent 6890 (Agilent technologies, USA) gas
chromatography instrument. In the gas chromatographic
system, a catabletary column (Agilent J&W DB-5ms Ultra
Inert 30m × 0.25mm, ﬁlm thickness 0.25µm) was used.
Helium carrier gas was used at a constant ﬂow rate of
1.0mL ∗ min−1.O n eµL of derivatized samples was injected
intotheGC/MSinstrument,andsplitlessinjectionmodewas
used. To acquire a well separation, the column temperature
wasinitiallymaintainedat80◦Cfor2minandthenincreased
from 80 to 140◦C at the rate of 10◦C/min for 6min. Then,
the column temperature was increased to 240◦C at the rate
of 4◦C/min for 25min. After that, the column temperature
was increased to 280◦C at the rate of 10◦C/min for 4min and
held for 3min. The temperatures of the injection port, the
interface, and source temperature were set at 280◦C, 260◦C,
and 230◦C, respectively. The measurements were made with
electronimpactionization(70eV)inthefullscanmode(m/z
30–550). The solvent posttime was set to 5min.
2.5. Data Analysis. Due to experimental variations and
column aging, shifts in retention time between ﬁngerprints
occur. When the total ion current chromatograms (TICs)
were obtained, peak-alignment or warping techniques are
commonly applied to compensate for minor shifts in
retention times. Thus, in the subsequently data processing,
the same variable manifested synchronous information in
every proﬁle. So all the GC-MS raw ﬁles after being con-
verted to CDF format via the software come with AgilentEvidence-Based Complementary and Alternative Medicine 3
MSD workstation, and were subsequently processed by the
XCMS toolbox (http://metlin.scripps.edu/download/) using
XCMS’s default settings with the following exceptions: xcms-
Set(fullwidthathalf-maximum:fwhm =5;S/Ncutoﬀvalue:
snthresh = 10, max = 15), and group (bw = 5). The resulting
table(CSVﬁle)wasexportedintoMicrosoftExcel(Microsoft
Inc., USA), where normalization was performed prior
to multivariate analyses. The resulting three-dimensional
matrix involving peak index (RT-m/z pair), sample names
(observations), and normalized peak area percent was
introduced into Simca-P 11.5 Software package (Umetrics,
Umea,Sweden)forpartialleastsquares-discriminateanalysis
(PLS-DA). Diﬀerential variables between CG and HBCG
were generated from loadings plot. To ﬁnd the inﬂuential
metabolites responsible for the separation, we calculated the
variable importance for the projection (VIP) values [18].
Variables with VIP values exceeding 1.5 were ﬁrst selected.
In a second step, those variables were further compared by
Mann-Whitney U-test to conﬁrm the changed metabolites
in SPSS 17.0 (SPSS, Chicago, IL, USA) with the threshold
of P value set at 0.05. Those variables, then, were identiﬁed
by searching in NIST 2005 database and veriﬁed by stan-
dards. References and the Kyoto Encyclopedia of Genes and
Genomes (KEGG) (http://www.genome.ad.jp/kegg/)w e r e
based to give the biochemical interpretation of changed
metabolites aﬀected by HBC.
3. Results
3.1. Metabolic Proﬁles of Cirrhosis Patients and Healthy
Control. One µL aliquots of supernatants of all the urine
samples, after a two-step derivatization, extraction and
dryness, were injected into GC/MS for analysis with the
methoddescribedpreviously.PLS-DAanalysiswasemployed
to discriminate HBCG and CG, and the score plot with
R2Y = 0.888 and Q2Y = 0.792 is shown in Figure 1(a).
In this map, HBCG could be absolutely separated from
healthy group. The results might demonstrate that the urine
metabolic proﬁles had changed signiﬁcantly.
Aloadingplotwasconstructedtoindicatethemostinﬂu-
ential variables according to their respective contributions
to the discrimination between the 2 groups (Figure 1(b)).
The further away from the main cluster, the greater inﬂuence
the variables have on the PLS-DA scores plot. Every variable
could be identiﬁed by the measured m/z value and NIST
database.Themetabolites’names,correspondingVIPvalues,
and changed trend compared with the healthy group are
presented in Table 1, simultaneously.
3.2. Biochemical Interpretation
3.2.1. Disorder of Immunity. Alanine and tyrosine, which are
the substrates of alanine transaminase (ALT) and aspartate
aminotransferase (AST), respectively, were upregulated in
HBCG.AndALTandASTwillincreasewhenactivatedCD4+
and CD8+ lymphocytes recognize various HBV-derived
proteins located on the surface of infected hepatocytes [19]
(summarized in Figure 2). So the increase of alanine and
Table 1: Identiﬁcation results and the changed trend of diﬀerential
metabolites of hepatitis-B-caused Cirrhosis subjects compared to
healthy group.
Number Metabolites RT (min) VIP
Changing trend
compared with
HG
1 Butanoic acid 5.29 2.25 ↑∗∗
2 Propanedioic acid 5.98 1.81 ↑∗∗
3 Hexanedioic acid 6.03 1.97 ↓∗∗
4 L-Alanine 8.06 2.28 ↑∗∗
5 Thiourea 9.75 1.73 ↓∗∗
6 acrylic acid 12.91 1.55 ↓∗∗
7 L-Proline 16.9 2.12 ↑∗∗
8 Methionine 17.8 1.57 ↑∗∗
9 Phenol 27.87 2.08 ↑∗∗
10 Benzoic acid 31.71 1.59 ↓∗∗
11 Benzenamine 31.79 1.97 ↑∗∗
12 Tyrosine 32.49 1.75 ↑∗∗
13 1,4-Butanedioic acid 34.41 1.92 ↑∗∗
14 DL-Tryptophan 34.44 1.83 ↑∗∗
15 L-Lysine 34.75 2.11 ↑∗∗
16 Isothiourea 34.78 2.04 ↑∗∗
17 Benzyl alcohol 35.08 1.61 ↑∗∗
18 Indole 36.21 2.03 ↑∗∗
19 Propanoic acid 36.4 1.64 ↑∗∗
20 Hexanoic acid 36.71 2.26 ↑∗∗
21 n-Butylamine 36.78 1.88 ↑∗∗
22 Acetic acid 36.81 1.69 ↑∗∗
23 Pentanoic acid 36.89 1.64 ↑∗∗
24 Tyrosyl-cysteine
methyl ester 37.37 2.04 ↑∗∗
The levels of diﬀerential metabolites were labeled with (↓) downregulated
and (↑) upregulated (∗∗P<0.01).
tyrosine might suggest that HBC was correlated with the
disorderofimmunesystem,whichwasinagreementwiththe
previous report that chronic HBV infection develops in the
setting of impaired immune reactions or a relatively tolerant
immune system status [20].
3.2.2.EnergyMetabolism. Alanineandprolineareprecursors
of pyruvate which can convert to acetyl-coenzyme A (Acetyl-
CoA) and is the main input for a series of reactions known
as TCA cycle. The increased level of alanine and proline in
HBCG might indicate that HBCG relieves the inhibition of
proline iminopeptidase (PIP) and activates the biosynthesis
of pyruvate to increase carbohydrate catabolism [20].
3.2.3. ABC Transporters. The signiﬁcantly changed metabo-
lites in this study, proline, lysine, and alanine, participated
the pathway of ABC transporters, which was found in
database KEGG. Liver is the most active site of cholesterol
metabolism, and the content of cholesterol is closely corre-
lated with cirrhosis [21]. However, ABC transporters play4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: (a) PLS-DA score plot between CG and HBCG. Black dots and red triangles refer to healthy subjects and hepatitis-B-caused
Cirrhosis subjects, respectively. (b) PLS-DA loading plot from HBCG and CG.
ollagen
Fermentation by
colonic bacteria
Butyrate Prop
p
ionate Acetate
Short
t
chain tatty acid
Phenols
Indoles
P
P
ro ein and absorption
IFN-γ, TNF-α ntiviral
C
Immune system
A
A
lanine
ALT
yruvic acid
Tyrosine
AST
4- ydroxyph he n y l p y r u v a t e
cirrhosis
Glycine betaine/ roline
Osmopro
o
tectant
Neutral a
a
mino acid/ istidie
Lysine/ rginine/ mith
h
ine
ABC transporters
Arginine and proline metabolism
L-proline HYP
ProX ProW ProV
OpuBC OpuBB OpuBA
NatB NatC NatA
NatD NatE
ArgT HisM
HisQ HisP
↑↑ ↑
↑
↑
↑
↑
↑
↑
CD8+,C D 4 + Tc e l l s
digestion
Post-HB
Figure 2: HBC-related pathway observed in this research.
an important role in secretion of cholesterol from liver into
bile [22]. The three changed amino acids might suggest
that HBC would be correlated with the dysfunction of ABC
transporters, which was in accordance with the literature
[23].
3.2.4. Protein Digestion and Absorption. T h ec o n t e n t so f
precollagentype IIIandcollagentypeIVincirrhosis subjects
are higher than normal ones, and they were reported as two
of the main factors for hepatitis ﬁbrosis and cirrhosis [23].
Butyrate, propionate, acetate, phenol, and indole are the
products of collagens after fermentation by colonic bacteria.
Those compounds that were detected increased compared
with healthy group in this research. Among them butyrate,
propionate, and acetate were retrieved in form of their acid
whichwerelistedasbutanoicacid,propanoicacid,andacetic
acid in Table 1. The results might prompt that the collagens
insubjectsofthisresearchhavebeenimproved,meaningthat
they may have been aﬀected with HBC.
In addition, Hydroxyproline, a product of proline
hydroxylation, is a common used biomarker of ﬁbrosis or
cirrhosis in animal experiments. In tissue of animals with
cirrhosis, the content of hydroxyproline is much higher than
healthy group [5, 6], which manifested in the increase of
proline in urine samples in this test. We have detected several
small molecules including alanine, tyrosine, butanoic acid,
propanoic acid, and acetic acid dovetailing with clinicalEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Score plot of PLS-DA for comparison among 4 ZHENG types. SDDES compared to LKYDS (a); SDDES compared to BSS (b);
LGDHS compared to LKYDS (c); LGDHS compared to BSS (d); LKYDS compared to BSS (e); SDDES compared to LGDHS (f).
biomarkers ALT, AST, precollagen type III, and collagen type
IV in this research, which suggests metabonomic technology
or further studies could help diagnose HBC.
3.3. ZHENG Diﬀerentiation. Four ZHENG types were dis-
tinguished by PLS-DA analysis. The model information is
shown in Table 2, and six maps of score plot are presented
in Figure 3. The results prompt that ZHENG diﬀerentiation
in TCM may be based on objective material, not only on
practitioners’ experience.
3.4. Eﬃciency of FZHY Tablet. The signiﬁcantly changed
metabolites of each group HBC patients from the healthy
subjects have been selected. And the potential biomarkers
of HBCG were previously listed in Table 1. The four TCM
ZHEGNs’ potential biomarkers arenot summarized in tables
but can be found on x-axis of Figure 4. The reversions of
these metabolites were based on to evaluate the therapeutic
eﬀect of FZHY tablet. Consequently, we found that there
werenosigniﬁcantlyreversedpotentialbiomarkersforallthe
subjects of HBC at both 12th week and 24th week. While for
LSYDS at 12th week, most inﬂuential metabolites reversed,6 Evidence-Based Complementary and Alternative Medicine
0
10
20
30
40
50
60
70
80
90
100
B
u
t
a
n
o
i
c
a
a
c
i
d
P
r
o
p
a
n
e
d
i
o
i
c
a
c
i
d
H
e
x
a
n
e
d
i
o
i
c
a
c
i
d
L
-
l
a
n
i
n
e
T
h
i
o
u
r
e
a
c
r
y
l
i
c
a
c
i
d
L
-
r
o
l
i
n
e
M
e
t
h
i
o
n
i
n
e
P
h
e
n
o
l
B
e
n
z
o
i
c
a
c
i
d
B
e
n
z
e
n
a
m
i
n
e
T
y
r
o
s
i
n
e
p
I
s
o
t
h
i
o
u
r
e
a
B
e
n
z
y
l
a
l
c
o
h
o
l
I
n
d
o
l
e
P
r
o
p
a
n
o
i
c
a
c
i
d
H
e
x
a
n
o
i
c
a
c
i
d
n
-
B
u
t
y
l
a
m
i
n
e
A
A
c
e
t
i
c
a
c
i
d
P
e
n
t
a
n
o
i
c
a
c
i
d
HBC
1
,
4
-
b
u
t
a
n
e
d
i
o
i
c
a
c
i
d
D
L
-
t
r
y
p
t
o
p
h
a
n
L
-
l
y
s
i
n
e
T
y
r
o
s
y
l
-
c
y
s
t
e
i
n
e
.
.
.
(a)
0
5
10
15
20
25
30
P
e
n
t
a
n
o
i
c
a
c
i
d
P
y
r
i
d
i
n
e
P
r
o
p
a
n
e
d
i
o
i
c
a
c
i
d
P
h
o
s
p
h
o
r
i
c
a
c
i
d
Q
u
i
n
o
l
i
n
e
H
i
s
t
i
d
i
n
e
B
e
n
z
e
n
e
a
c
e
t
i
c
a
c
i
d
B
e
n
z
y
l
a
l
c
o
h
o
l
P
e
n
t
a
n
o
i
c
a
c
i
d
P
h
t
h
a
l
i
c
a
c
i
d
G
l
y
c
i
n
e
A
l
a
n
i
n
e
B
e
n
z
o
i
c
a
c
i
d
P
h
e
n
o
l
B
u
t
a
n
e
d
i
o
i
c
a
c
i
d
D
i
b
e
n
z
o
f
u
r
a
n
H
e
x
a
n
o
i
c
a
c
i
d
A
c
e
t
i
c
a
c
i
d
SDDES
P
r
o
p
i
o
n
i
c
a
c
i
d
l
-
p
r
o
l
i
n
e
D
-
t
r
y
p
t
o
p
h
a
n
L
-
g
l
u
t
a
m
i
c
a
c
i
d
L
-
p
r
o
l
i
n
e
(b)
0
5
10
15
20
25
30
P
y
r
i
d
i
n
e
Q
u
i
n
o
l
i
n
e
E
t
h
y
l
c
i
t
r
a
t
e
I
n
d
o
l
e
b
u
t
y
r
i
c
a
c
i
d
G
l
y
c
i
n
e
P
h
e
n
o
l
P
r
o
p
a
n
e
d
i
o
i
c
a
c
i
d
P
i
p
e
r
o
n
a
l
P
a
r
o
x
y
p
r
o
p
i
o
n
e
B
e
n
z
o
i
c
a
c
i
d
A
c
e
t
i
c
a
c
i
d
LGDHS
L
-
p
r
o
l
i
n
e
L
-
m
e
t
h
i
o
n
i
n
e
N
-
b
e
n
z
o
y
l
g
l
y
c
i
n
e
.
.
.
N
-
a
c
e
t
y
l
t
y
r
a
m
i
n
e
2
,
2
’
-
b
i
t
h
i
o
p
h
e
n
e
L
-
v
a
l
i
n
e
5
-
m
e
t
h
y
l
a
n
t
h
r
a
n
i
l
i
c
.
.
.
1
H
-
i
n
d
o
l
e
-
3
-
.
.
.
D
L
-
t
r
y
p
t
o
p
h
a
n
3
-
b
u
t
e
n
-
2
-
o
n
e
l
-
p
r
o
l
i
n
e
1
(
2
H
)
-
n
a
p
h
t
h
a
l
e
n
o
n
e
E
t
h
y
l
v
a
n
i
l
l
i
n
(c)
0
5
10
15
20
25
30
35 LKYDS
P
y
r
i
d
i
n
e
Q
u
i
n
o
l
i
n
e
A
c
e
t
a
t
e
B
e
n
z
e
n
a
m
i
n
e
B
e
n
z
a
l
d
e
h
y
d
e
P
i
p
e
r
o
n
a
l
B
e
n
z
y
l
a
l
c
o
h
o
l
A
c
e
t
i
c
a
c
i
d
P
r
o
p
i
o
n
i
c
a
c
i
d
B
u
t
a
n
e
d
i
o
i
c
a
c
i
d
1
,
4
-
b
u
t
a
n
e
d
i
o
i
c
a
c
i
d
E
t
h
y
l
v
a
n
i
l
l
i
n
2
,
2
’
-
b
i
t
h
i
o
p
h
e
n
e
4
-
ﬂ
u
o
r
o
b
e
n
z
z
o
i
c
a
c
i
d
5
-
m
e
t
h
y
l
a
n
t
h
r
a
n
i
l
i
c
a
c
i
d
L
-
p
r
o
l
i
n
e
(d)
CG
Pre-oral
0
5
10
15
20
25
30
P
y
r
i
d
i
n
e
P
r
o
p
a
n
e
d
i
o
i
c
a
c
i
d
Q
u
i
n
o
l
i
n
e
H
i
s
t
i
d
i
n
e
P
e
n
t
a
n
e
t
h
i
o
i
c
a
c
i
d
P
e
n
t
a
n
o
i
c
a
c
i
d
P
h
t
h
a
l
i
c
a
c
i
d
I
n
d
o
l
e
b
u
t
y
r
i
c
a
c
i
d
E
t
h
y
l
c
i
t
r
a
t
e
G
l
y
c
i
n
e
A
l
a
n
i
n
e
B
e
n
z
e
n
e
a
c
e
t
i
c
a
c
i
d
B
e
n
z
o
i
c
a
c
i
d
P
h
e
n
o
l
Q
u
i
n
o
l
i
n
e
B
e
n
z
y
l
a
l
c
o
h
o
l
D
i
b
e
n
z
o
f
u
r
a
n
H
e
x
a
n
o
i
c
a
c
i
d
A
c
e
t
i
c
a
c
i
d
B
e
n
z
e
n
e
m
e
t
h
a
n
a
m
i
n
e
P
r
o
p
i
o
n
i
c
a
c
i
d
BSS
1
,
3
-
c
y
c
l
o
p
e
n
t
a
d
i
e
n
e
D
L
-
t
r
y
p
t
o
p
h
a
n
L
-
p
r
o
l
i
n
e
12week
24week
(e)
Figure 4: Five maps revealed the therapeutic eﬀect of FZHY tablet for hepatitis-B-caused cirrhosis (HBC) and four TCM ZHENG types,
respectively:spleendeﬁciencywithdampnessencumbrancesyndrome(SDDES),liver-gallbladderdampness-heatsyndrome(LGDHS),liver-
kidney yin deﬁciency syndrome (LKYDS), and blood stasis syndrome (BSS), by the changing trend of signiﬁcantly diﬀerential metabolites.
CGisshortforcontrolgroup;preoralineachgroupstandsforinformationbeforeinterventionofFZHYtablet;12thweekmeanseﬀectsafter
12-week intervention by FZHY tablet; 24th week means eﬀects after 24-week intervention. The x-axis represented the changed metabolites,
and the y-axis was average rank in Mann-Whitney U-test, representing the contents of metabolites.Evidence-Based Complementary and Alternative Medicine 7
Table 2: Model information of PLS-DA for comparison of 4
ZHENGs with each other.
Model Amount of
components R2YQ 2Y
SDDES and LKYDS 3 0.969 0.462
SDDES and BSS 3 0.922 0.106
LGDHS and LKYDS 3 0.922 0.0934
LGDHS and BSS 6 0.999 0.682
LKYDS and BSS 4 0.988 0.44
SDDES and LGDHS 5 0.999 0.549
and at 24th week, the reversion of potential biomarkers
showed good eﬃciency of FZHY for SDDES, as manifested
in Figure 4 (LKYDS and SDDES). As we can see, most
metabolites for LGDHS and BBS got further away from the
healthy group than pre-oral of FZHY.
4. Discussion
The potential biomarkers that discriminate HBCG and CG
were found by PLS-DA loading plot analysis. After retrieving
literaturesandthedatabaseKEGG,itwassupposedthatHBC
might correlate with the disorder of immune metabolism,
energy metabolism, ABC transporters, and protein diges-
tion and absorption. The ZHENG diﬀerentiation of HBC
demonstrated that a disease might be divided into more
than one pattern. Diﬀerent metabolic proﬁles or diﬀerent
phenotypes probably arise from disparate pathogenesis and
etiological factors. Consequently, every ZHENG should be
treated diﬀerently, which was in accordance with the theory
of ZHENG diﬀerentiation and treatment [24].
The results showed that subjects with deﬁciency syn-
d r o m e( S D D E Sa n dL K Y D S )a r em o r es u s c e p t i b l ef o rF Z H Y
tablet, which was in accordance with “boosting essence
supplementingdeﬁciency”intheprinciplesofrecipecompo-
sition. At24th week, subjectswithLKYDSdid not appearthe
eﬀectsasgoodasthatof12thweek,whichmaybeinterpreted
by the dynamic and developmental characteristics of disease.
The patients were diagnosed with LKYDS when enrolled,
but after 12 weeks their ZHENG might have changed. So
the treatment rules should be changed correspondingly,
which precisely manifested the personalized medicine. In
respect of that subjects with LGDHS and BSS still had no
signs of recovery during the 24-week treatment, those two
ZHENG types seemed not suitable for FZHY tablet. So the
correspondence between ZEHNG and formula, called “fang
zheng dui ying” in TCM, is very important [25]. And it is the
main treatment principle after ZHENG diﬀerentiation.
To acquire results with high reliability and accuracy,
large amount of samples should be collected. And after the
multicenter and multiregional trial validation, biomarkers
could only be transformed into clinical applications. In
addition, if Metabonomics is validated by other “omics” or
biochemical methods, it would be more convincing.
5. Conclusion
Subjects with HBC were distinguished from the healthy
control with the method of Metabonomics based on GC/MS
analysis and multivariate statistical techniques. The four
ZHENGs in this study were also classiﬁed by PLS-DA. With-
out ZHENG diﬀerentiation, the eﬃciency of FZHY tablet for
patients with HBC was not signiﬁcant, through the holistic
evaluatingapproach.Howeveriftheobjectsoftreatmentaim
at subjects with spleen deﬁciency with dampness encum-
brance syndrome or liver-kidney yin deﬁciency syndrome,
the therapeutic eﬀects would be increased remarkably. And
at ones with liver-gallbladder dampness-heat syndrome, and
blood stasis syndrome, within 24 weeks not any eﬀects could
be observed. As a result, the treatment eﬀect of FZHY tablet
indicated that accurately ZHENG diﬀerentiation could guide
the appropriate TCM treatment in HBC. And this study
indicated that Metabonomics technology can be utilized to
evaluate the therapeutic eﬀect of TCM recipes based on
ZHENG diﬀerentiation and Treatment.
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